I for one hope that they have reconsidered taking the penalty. Unless it is some massive penalty, I think its worth taking it so we know where we stand.

If the results are good, but not quite good enough to get a halt, we could benefit from having the data with respect to accelerating enrollment.

We have an adaptive trial, so I believe we can increase the size of it if needed.

If our data shows a pvalue of say .06, but a 50% reduction in mortality, I would think that data would serve to substantially increase enrollment.